PRL and breast carcinoma: An association has been found between the use of SSRIs and risk reduction, in some studies it is more evident than in others, of colorectal cancer [439-441], lung cancer [442] and lymphoma/leukemia [443-445]; although the use of SSRIs may stimulate the secretion of prolactin, a potential breast cancer promoter, clinical studies have refuted an increased risk of breast cancer with SSRIs’ use [446-448].